Ratings OSE Immunotherapeutics

Equities

OSE

FR0012127173

Market Closed - Euronext Paris Other stock markets 11:36:04 2024-05-03 am EDT			Pre-market 02:41:26 am
6.2 ^EUR	-0.64%		6.215	+0.24%

Apr. 17	OSE: licensing agreement with AbbVie enters into force	CF
Apr. 17	OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Over the last twelve months, the sales forecast has been frequently revised upwards.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
Based on current prices, the company has particularly high valuation levels.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
OSE IMMUNOTHERAPEUTICS	+44.86%	144M	D
MODERNA, INC.	+25.69%	47.9B	B-
LONZA GROUP AG	+46.90%	41.42B	A
IQVIA HOLDINGS INC.	-3.46%	40.7B	B
CELLTRION, INC.	-6.20%	28.92B	C
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B	B
BIO-TECHNE CORPORATION	+0.17%	12.15B	B+
MEDPACE HOLDINGS, INC.	+28.07%	12.14B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes